Successful Treatment of Clinically Diagnosed Cancer-Associated Retinopathy with Intravitreal Dexamethasone Implant Followed by 0.18 mg Fluocinolone Implant without Systemic Immunosuppression.
Lingling HuangPaul YangChristina FlaxelEric SuhlerPhoebe LinPublished in: Retinal cases & brief reports (2024)
The sustained improvements with intravitreal corticosteroid monotherapy suggest potential advantages using local therapy over systemic treatment. Long term follow-up is warranted. Further research is needed to evaluate the efficacy of using 0.18mg fluocinolone implant (YUTIQ) to treat CAR.
Keyphrases
- soft tissue
- vascular endothelial growth factor
- diabetic retinopathy
- combination therapy
- age related macular degeneration
- low dose
- high dose
- stem cells
- randomized controlled trial
- open label
- clinical trial
- mesenchymal stem cells
- human health
- optical coherence tomography
- risk assessment
- bone marrow
- endothelial cells
- drug induced